SHARE

Sanofi to acquire UK biotech Vicebio for $1.15bn in respiratory vaccine deal 

Sanofi will acquire UK biotech Vicebio for $1.15bn, including up to $450m in milestones. The deal adds a non-mRNA RSV and hMPV vaccine plus technology to enable vaccine storage at standard refrigeration. Completion expected in Q4 2025.

Certification Note

Certified B Corporation” is a trademark licensed by B Lab, a private non-profit organization, to companies like ours that have successfully completed the B Impact Assessment (“BIA”) and therefore meet the requirements set by B Lab for social and environmental performance, accountability, and transparency. It is specified that B Lab is not a conformity assessment body as defined by Regulation (EU) No 765/2008, nor is it a national, European, or international standardization body as per Regulation (EU) No 1025/2012. The criteria of the BIA are distinct and independent from the harmonized standards resulting from ISO norms or other standardization bodies, and they are not ratified by national or European public institutions.